44 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
with all statutes, rules and regulations applicable to the testing, development, manufacture, packaging, processing, use, distribution, marketing
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
revenue, our business and our results of operations.
The research, development, testing, manufacturing, labeling, packaging, approval, promotion … on third parties, such as CROs, investigational product packaging, labeling and distribution, laboratories, medical institutions and clinical
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
to generate revenue, our business and our results of operations.
The research, development, testing, manufacturing, labeling, packaging, approval … .
We rely on third parties, such as CROs, investigational product packaging, labeling and distribution, laboratories, medical institutions
8-K
EX-1.1
lpuzfgyo zfvnfklid
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
mgy66 cr4zas
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
ple023c e434q66d0
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
8x6udsu07f 1c62
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
5vocahwb g0m06nksi
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
t4g76792g13s80iku e4
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
s11tbaaobw6vh
23 Jun 20
Prospectus supplement for primary offering
4:06pm
424B5
xs6 55hn7b0nxl
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
u1k4b3gqewg0
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B3
8oowfeevqjfrjlj348c7
12 Apr 19
Prospectus supplement
4:41pm